Jefferies analysts downgraded Apple (NASDAQ:AAPL) stock to Underperform from Hold, reducing the price target to $200.75 from $211.84, signaling a potential 13% downside. The downgrade reflects concerns over Apple's fiscal Q1 2025 earnings and guidance, with analysts predicting the company will miss its revenue growth target of 5% and guide for low single-digit growth in Q2.
The bearish outlook stems from weak iPhone sales and subdued expectations for the iPhone 17 and 18, driven by “slower AI uptake and commercialization.” Jefferies revised their Q1 iPhone shipment forecast to a 2% decline from a 1% growth, citing a 4% year-over-year drop in shipments according to IDC data. Demand in China has reportedly dropped sharply, while other markets may see marginal growth.
Other Apple products like iPads and MacBooks face challenges amid a sluggish consumer electronics market. Optimism for Chinese demand is dampened by new government policies limiting subsidies for most iPhone models. Additionally, demand for the SE4 could fall short, competing against used iPhone 13/14 models rather than Android alternatives.
Jefferies also flagged a subdued outlook for smartphone AI, noting that US consumers find the feature less useful. Delays in Apple’s advanced packaging roadmap for AI capabilities further raise concerns. Analysts believe AI monetization challenges could slow iPhone upgrade cycles despite potential new form factors.
Jefferies slashed Apple’s earnings per share (EPS) estimates for FY25 and FY26 by 2% to 23%, with projections now 4% below consensus. These factors, combined with slower AI adoption, contribute to the cautious outlook for Apple's growth trajectory.


Anthropic Eyes $350 Billion Valuation as AI Funding and Share Sale Accelerate
Global PC Makers Eye Chinese Memory Chip Suppliers Amid Ongoing Supply Crunch
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates
Tencent Shares Slide After WeChat Restricts YuanBao AI Promotional Links
Bitcoin Hits $100K Milestone Amid Optimism Over Trump Policies
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks
Reliance Industries Surges on Strong Quarterly Profit, Retail Recovery
SoftBank and Intel Partner to Develop Next-Generation Memory Chips for AI Data Centers
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Why your retirement fund might soon include cryptocurrency
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Trump Backs Nexstar–Tegna Merger Amid Shifting U.S. Media Landscape
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Elliott Investment Management Takes Significant Stake in BP to Push for Value Growth
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
Why the Middle East is being left behind by global climate finance plans 



